Biotage AB Statistics
Total Valuation
Biotage AB has a market cap or net worth of 1.17 billion. The enterprise value is 1.15 billion.
| Market Cap | 1.17B |
| Enterprise Value | 1.15B |
Important Dates
The next estimated earnings date is Wednesday, July 16, 2025.
| Earnings Date | Jul 16, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
| Current Share Class | n/a |
| Shares Outstanding | n/a |
| Shares Change (YoY) | +3.44% |
| Shares Change (QoQ) | +0.01% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | 75.19M |
Valuation Ratios
The trailing PE ratio is 45.98.
| PE Ratio | 45.98 |
| Forward PE | n/a |
| PS Ratio | 5.98 |
| PB Ratio | 3.05 |
| P/TBV Ratio | 12.35 |
| P/FCF Ratio | 44.41 |
| P/OCF Ratio | 33.69 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 23.06, with an EV/FCF ratio of 43.70.
| EV / Earnings | 45.24 |
| EV / Sales | 5.69 |
| EV / EBITDA | 23.06 |
| EV / EBIT | 33.32 |
| EV / FCF | 43.70 |
Financial Position
The company has a current ratio of 2.53, with a Debt / Equity ratio of 0.06.
| Current Ratio | 2.53 |
| Quick Ratio | 1.53 |
| Debt / Equity | 0.06 |
| Debt / EBITDA | 0.49 |
| Debt / FCF | 0.90 |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is 6.59% and return on invested capital (ROIC) is 5.09%.
| Return on Equity (ROE) | 6.59% |
| Return on Assets (ROA) | 4.25% |
| Return on Invested Capital (ROIC) | 5.09% |
| Return on Capital Employed (ROCE) | 7.91% |
| Revenue Per Employee | 314,086 |
| Profits Per Employee | 40,842 |
| Employee Count | 680 |
| Asset Turnover | 0.40 |
| Inventory Turnover | 1.66 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -48.01% in the last 52 weeks. The beta is 0.89, so Biotage AB's price volatility has been lower than the market average.
| Beta (5Y) | 0.89 |
| 52-Week Price Change | -48.01% |
| 50-Day Moving Average | 15.95 |
| 200-Day Moving Average | n/a |
| Relative Strength Index (RSI) | 34.13 |
| Average Volume (20 Days) | 548 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Biotage AB had revenue of 195.36 million and earned 25.40 million in profits. Earnings per share was 0.32.
| Revenue | 195.36M |
| Gross Profit | 122.34M |
| Operating Income | 33.37M |
| Pretax Income | 28.89M |
| Net Income | 25.40M |
| EBITDA | 45.13M |
| EBIT | 33.37M |
| Earnings Per Share (EPS) | 0.32 |
Balance Sheet
The company has 41.84 million in cash and 23.71 million in debt, giving a net cash position of 18.13 million.
| Cash & Cash Equivalents | 41.84M |
| Total Debt | 23.71M |
| Net Cash | 18.13M |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 383.15M |
| Book Value Per Share | 4.79 |
| Working Capital | 72.63M |
Cash Flow
In the last 12 months, operating cash flow was 34.67 million and capital expenditures -8.37 million, giving a free cash flow of 26.30 million.
| Operating Cash Flow | 34.67M |
| Capital Expenditures | -8.37M |
| Free Cash Flow | 26.30M |
| FCF Per Share | n/a |
Margins
Gross margin is 62.62%, with operating and profit margins of 17.08% and 13.00%.
| Gross Margin | 62.62% |
| Operating Margin | 17.08% |
| Pretax Margin | 14.79% |
| Profit Margin | 13.00% |
| EBITDA Margin | 23.10% |
| EBIT Margin | 17.08% |
| FCF Margin | 13.46% |
Dividends & Yields
Biotage AB does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | 50.20% |
| Buyback Yield | -3.44% |
| Shareholder Yield | -3.44% |
| Earnings Yield | 2.18% |
| FCF Yield | 2.25% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Biotage AB has an Altman Z-Score of 10.32.
| Altman Z-Score | 10.32 |
| Piotroski F-Score | n/a |